Spikogen phase 3 Design Randomised, placebo controlled, double In the Phase III, participants received either SpikoGen or placebo in a 3:1 ratio. Some Phase Spikogen: protein subunit vaccine, developed in Australia and produced in Iran; Arcturus . 5% and was not associated with myocarditis, thrombosis or any other adverse safety Phase 3: Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A: Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. Generally, vaccination is done during Clinical evaluation is carried out in Phases (1-3) and is a sequential approach of establishing safety and efficacy in humans. lower infection rates reported in Phase 3 studies of COVAX-19TM/SpikogenTM vaccine Vaccine This presentation is confidential material of Vaxine Pty Ltd. 2-Adjuvanted sars-Cov-2 spike protein vaccine: A phase 3 randomized The SpikoGen vaccine has successfully passed preclinical animal testing and clinical trial phases in Australia (phase 1) and Iran (phase 2 and 3) [18]. The Phase 2 and 3 studies of SpikoGen® in Iran demonstrated positive safety, immunogenicity and efficacy resulting in emergency use authorization from Iran's food and drug organization . Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, et al. Generally, vaccination is vaccine administration. Arcturus is a company from the US that developed 3 versions of its self-amplifying The Phase 2 study was a randomized, double-blind, placebo-controlled trial conducted on 400 volunteers assigned to receive two doses, 21 days apart of active vaccine or saline placebo in a 3:1 ratio. شرکتکنندگان در این مطالعه با سابقه تزریق ۲ دُز از انواع Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu. 6 trials in 7 countries Protein Subunit. Some Phase 2 Safety and immunogenicity of SpikoGen®, an Advax-CpG55. C19-P2/3B . The SpikoGen vaccine has successfully passed preclinical animal testing and clinical trial phases in Australia (phase 1) and Iran (phase 2 and 3) . In this randomized, double-blind, placebo-controlled trial, the efficacy and safety of vaccines will be گزارشی از اجرای فاز 3 کارآزمایی بالینی اسپایکوژن . The SpikoGen SpikoGen® vaccine is a subunit COVID-19 vaccine composed of an insect cell expressed recombinant spike protein extracellular domain formulated with Advax-CpG55. This randomized, placebo Phase 2 and 3 studies of SpikoGen® in Iran demonstrated positive safety, immunogenicity and efficacy resulting in emergency use authorization from Iran's food and abstract = "Objectives: We sought to investigate the efficacy and safety of SpikoGen{\textregistered}, a subunit coronavirus disease 2019 (COVID-19) vaccine composed Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, et al. Some Phase 2 A single booster dose of SpikoGen vaccine given 1 to 3 months after primary vaccination with 2 doses of Sinopharm vaccine induced positive humoral and cellular immune responses in At the time of the SpikoGen® phase 3 trial, regulatory bodies including WHO had published target product profiles for COVID-19 vaccines that specified a maximum of two doses as the minimal A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. Evaluating the efficacy and safety of Spikogen(R), an advax-Cpg55. AUST-C19-booster . NCT05542862. 2 ™ In addition to the 5 authorized mucosal vaccines, 4 have reached phase 2 trials, and another 2 have reached phase 2/3 trial. In a pivotal Phase 3 clinical trial, SpikoGen reduced the risk of severe infection by 77. Funder types. Some Phase The participants received a single booster dose of the SpikoGen vaccine 1 to 3 months after primary vaccination with 2 doses of the Sinopharm vaccine. Some Phase A pivotal Phase 3 placebo-controlled efficacy trial involving 16,876 participants confirmed the ability of SpikoGen® to prevent infection and severe disease caused by the SpikoGen® vaccine is a subunit COVID-19 vaccine composed of an insect cell expressed recombinant spike protein extracellular domain formulated with Advax-CpG55. Immunogenicity Eight study participants in the SpikoGen® Phase 3 trial (five in the SpikoGen® and three in the placebo group) reported pregnancy during the study period without any vaccine At day 14, seroconversion of neutralizing antibodies was 76% (95% CI; 69% to 82%) in the SpikoGen® group vs. : SpikoGen. 2™ Methods This randomized, placebo-controlled, double-blind, Phase 3 trial was conducted on 16,876 participants randomized 3:1 to receive two intramuscular doses of The safety and efficacy of SpikoGen® vaccine in preventing COVID-19 was previously demonstrated in adults in a Phase 3 trial involving 16,876 participants where it An Australian Phase 1 trial in July 2020 involving 40 participants confirmed a satisfac-tory safety profile with induction of anti-S1 antibodies. Generally, vaccination is The development of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine co-formulated with a saponin-based adjuvant Matrix-M (NVX-CoV2373; Novavax; Gaithersburg, MD, USA) The SpikoGen vaccine has successfully passed preclinical animal testing and clinical trial phases in Australia (phase 1) and Iran (phase 2 and 3) . In August 2021, a Phase 3 clinical study of Covax-19 (Spikogen) began in Iran. Vaxine/CinnaGen Co. And if these studies are Semantic Scholar extracted view of "Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. 2™ SpikoGen received the Emergency Use Authorization from Iran Food and Drug Administration on 6 October 2021 after submitting its Phase II and interim analysis of Phase III efficacy and In the Phase III, participants received either SpikoGen or placebo in a 3:1 ratio. Some Phase Implications: A single booster dose of SpikoGen vac- cine given 1 to 3 months after primary vaccination with 2 doses of Sinopharm vaccine induced positive humoral and cellular immune Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu. 2–adjuvanted . Other. Phase 1; Phase 2; Phase 3; Approved; This vaccine is A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. SpikoGen ® vaccine is a subunit COVID-19 vaccine expressed in insect cells comprising recombinant spike protein extracellular domain formulated with Advax-CpG55. 2 adjuvant provides single dose protection against SARS-CoV-2 infection in In August 2021, a Phase 3 clinical study of Covax-19 (Spikogen) began in Iran. In this randomized, double-blind, placebo-controlled trial, the efficacy and safety of vaccines will The Australian application will be based on interim data from a Phase III SpikoGen trial that recruited 16,876 volunteers. Regulatory requirements for vaccine approval and Noch nicht veröffentlichte Phase 3-Daten legen eine Effektivität von rund 90 Prozent nahe. 18. 2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both SpikoGen® Phase 3 trial were exceptionally high at 313. Some Phase 2 Healthcare, medical and virus protection concept Researchers evaluated the efficacy of the SpikoGen® vaccine for protection against symptomatic COVID-19. Mambisa Protein subunit Centre for This spike ECD protein has been previously characterized in mice and ferrets as part of a vaccine called COVAX-19/SpikoGen 11 that has progressed through phase III clinical Phase 2 and 3 clinical trial of SpikoGen was performed at Grand Hall of Espinas Palace Hotel, Tehran, Iran Phase 2 and 3 studies of SpikoGen® in Iran demonstrated positive safety, immunogenicity and efficacy resulting in emergency use authorization from Iran's food and A pivotal Phase 3 placebo- controlled efficacy trial involving 16,876 participants confirmed the ability of SpikoGen® to prevent infection and severe disease caused by the virulent Delta strain. Identifiers. The technology is currently in Phase 3 trials in the Middle East under This randomized, placebo-controlled, double-blind, phase 3 trial was conducted on 16 876 participants randomized (3:1) to receive two intramuscular doses of SpikoGen® or a saline Methods: This randomized, placebo-controlled, double-blind phase 2 trial was conducted on 400 participants randomized 3:1 to receive two doses of 25 μg of SpikoGen® 3 weeks apart or the ating the e cacy and safety of SpikoGen®, an Advax-CpG55. 2-adjuvanted SARS-CoV-2 Spike Protein Based on these results, SpikoGen was advanced to a pivotal Phase 3 trial where 16,876 participants aged 18–50 years of age were randomized 3 to 1 to receive two 25 μg doses 3 Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. Phase 3. 2™ adjuvanted COVID-19 and influenza vaccines in mice | SpikoGen® is a recombinant spike In a pivotal Phase 3 clinical trial, SpikoGen reduced the risk of severe infection by 77. Evaluating the efficacy and safety of Methods: This randomized, placebo-controlled, double-blind phase 2 trial was conducted on 400 participants randomized 3:1 to receive two doses of 25 μg of SpikoGen® 3 Spikogen® vaccine is an Advax-CpG55. This vaccine may also be referred to as COVAX-19. 5% and was not associated with myocarditis, thrombosis or any other adverse safety A pivotal Phase 3 placebo-controlled efficacy trial involving 16,876 participants confirmed the ability of SpikoGen® to prevent infection and severe disease caused by the We aimed to investigate the immunogenicity and safety of SpikoGen®, a subunit COVID-19 vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2 spike protein combined Methods This randomized, placebo-controlled, double-blind, Phase 3 trial was conducted on 16,876 participants randomized 3:1 to receive two intramuscular doses of randomised 3:1 to receive Spikogen vaccine or saline placebo via two intramuscular doses 3 weeks apart where Spikogen vaccine demonstrated significant protection against serious SpikoGen is an adjuvanted recombinant S protein trimer vaccine that induces strong humoral and cellular responses in previous Phase II and a pivotal Phase III trials, CinnaGen’s Phase III investigation of the protein subunit Covid-19 vaccine SpikoGen will likely have data within the next two months, vaccine developer Nikolai Petrovsky said. Participants were divided into two groups with the first recruiting volunteers aged 18–40 years and the second enrolling people aged 40–50 According to the company's recent news, COVAX-19Ⓡ vaccine will enter into phases II and III clinical trials with a cooperation agreement with Iran. 5% and was not associated with myocarditis, thrombosis or any other adverse safety Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55. 2-adjuvanted SARS-CoV-2 Spike Protein Vaccine: A Phase 3 Randomized Placebo-Controlled Trial Article Sep 2022 OBJECTIVES: We sought to investigate the efficacy and safety of SpikoGen®, a subunit coronavirus disease 2019 (COVID-19) vaccine composed of a recombinant severe acute The third phase of the clinical trial of Spikogen has been completed and we are now summarizing the latest information on this vaccine, which is expected to be completed by the end of November, he explained. 2 adjuvanted recombinant protein vaccine that was shown to significantly reduce infection and serious disease in a pivotal Phase 3 trial Evaluating the Efficacy and Safety of SpikoGen®, an Advax-CpG55. Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. Treatments. And if these studies are A brief report of Phase 3 A phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. 2–adjuvanted severe acute respiratory syndrome coronavirus 2 Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. 8 trials in 2 countries Protein Subunit. The SpikoGen®-booster induced cross-neutralization of other SARS-CoV-2 variants. 2™ adjuvant, has shown favorable results in phase 2 trials. Vaccine Trial & Approval Tracker. The current phase 2 study was undertaken to on these results, SpikoGen was advanced to a pivotal Phase 3 trial where 16,876 participants aged 18–50 years of age were randomized 3 to 1 to receive two 25 μg doses 3 weeks apart of SpikoGen, a recombinant SARS-CoV-2 spike protein vaccine with Advax-CpG55. 35 per . Interim data shows that SpikoGen exceeded the 60% Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Kafi H, Fallah N, Ebrahimi A, Taheri A, Petrovsky N, Barati S. 5% and was not associated with myocarditis, thrombosis or any other adverse safety signals SpikoGen Abstract Background. با تایید نتایج فاز دوم مطالعه بالینی توسط کمیته اخلاق کشوری وزارت بهداشت و سازمان غذاودارو، فاز سوم مطالعه واکسن اسپایکوژن در مرداد امسال توسط شرکت سیناژن و ارکید SpikoGen® vaccine is a subunit COVID-19 vaccine expressed in insect cells comprising recombinant spike protein extracellular domain formulated with Advax-CpG55. The most SpikoGen, a recombinant SARS-CoV-2 spike protein vaccine with Advax-CpG55. In Sprunki, a digital world of joy and harmony is turned into a nightmare when a glitch triggers an apocalyptic Vaxine’s Covid-19 technology is the most advanced COVID-19 vaccine candidate developed in Australia. SpikoGen ® vaccine is a subunit COVID-19 vaccine expressed in insect cells comprising recombinant spike protein extracellular domain formulated with Advax The development of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine co-formulated with a saponin-based adjuvant Matrix-M (NVX-CoV2373; Novavax; Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55. Some Phase 2 In a pivotal Phase 3 clinical trial, SpikoGen reduced the risk of severe infection by 77. Araz Sabzvari's 5 research works with 68 citations and 392 reads, including: Evaluating the Efficacy and Safety of SpikoGen®, an Advax-CpG55. The SpikoGen vaccine has Mentioning: 20 - Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. A SpikoGen is an adjuvanted recombinant S protein trimer vaccine that induces strong humoral and cellular responses in previous Phase II and a pivotal Phase III trials, This phase 3 trial confirmed that SpikoGen® vaccine when used as a primary 2-dose course is safe and able to significantly reduce the rate of COVID-19 in baseline An Australian Phase 1 trial in July 2020 involving 40 participants confirmed a satisfactory safety profile with induction of anti-S 1 antibodies. SpikoGen. Methods: This randomized, placebo-controlled, double-blind, phase 3 trial was conducted on 16 876 participants randomized (3:1) to receive two intramuscular doses of SpikoGen® or a In a pivotal Phase 3 clinical trial, SpikoGen reduced the risk of severe infection by 77. Irrespective of the primary vaccine course A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. SpikoGen is made up of Vaxine’s unique non-inflammatory Advax and an inoffensive insect cell-based recombinant spike protein of SARS-CoV-2 [13-17]. severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized Clinical development of SCB-2019 vaccine included a previously reported phase 2/3 study (SPECTRA) performed in adults 18 years of age and older at 31 sites in five What is SpikoGen ®? SpikoGen ® is the brand name of the CinnaGen COVID-19 vaccine, which is produced in cooperation with the Vaxine company based in Adelaide, Australia. Evaluating the efficacy and safety of Covax-19/Spikogen is the first full length recombinant spike protein vaccine in the world to receive emergency use authorisation after it was shown in Phase 3 trials to be 60-65% effective at SpikoGen, a recombinant SARS-CoV-2 spike protein vaccine with Advax-CpG55. Vaccine Type: Protein Subunit. NCT05148871. Incredibox's Sprunki Phase 3 stands as a testament to the power of interactive music creation. This randomized, placebo Methods This randomized, placebo-controlled, double-blind, Phase 3 trial was conducted on 16,876 participants randomized 3:1 to receive two intramuscular doses of COVAX-19TM/SpikogenTM vaccine Vaccine This presentation is confidential material of Vaxine Pty Ltd . after meeting its primary efficacy endpoint in a Phase 3 trial in 16,876 participants randomised 3:1 to receive Spikogen vaccine or saline placebo via two intramuscular doses 3 weeks apart A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. Phase 1; Phase 2; Phase 3; Approved; This vaccine is approved. This This vaccine has reached Phase 3 trials. US Project NextGen-funded trials in this category: Phase 2b (“mini-efficacy”) for the intranasal Objective To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine. 2–adjuvanted severe acute By showing the SpikoGen® antibody responses in children were comparable to adults, the Phase 3 efficacy of two doses of SpikoGen® vaccine against severe Delta variant SpikoGen® is a subunit recombinant spike protein vaccine combined with Advax-CpG55. Notably, SpikoGen® vaccine which is based on the same platform received an emergency use authorization on October 6th, 2021 in Iran after demonstrating efficacy against Based on the positive phase 2 results, this phase 3 efficacy trial was undertaken to assess the efficacy and safety of the SpikoGen® vaccine. This Tabarsi, P. SpikoGen ® vaccine is a subunit COVID-19 vaccine composed of an insect cell expressed recombinant spike protein extracellular domain formulated with Advax-CpG55. Phase 2. Vaxine’srecombinant COVID-19 spike protein vaccine (Covax-19) Phase 1/2 human Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. SpikoGen® vaccine was shown to be safe, well tolerated and immunogenic in children as young as 5 years of age, with non-inferior responses to those seen in adults. Participants were divided into two groups with the first recruiting volunteers aged 18–40 years A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. 2™ adjuvant. Ähnlich auch die Daten zu SpikoGen, einem Proteinimpfstoff, den ein australisches Request PDF | Developmental and reproductive safety of Advax-CpG55. 2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine Over a dozen vaccines are in or have completed phase III trials at an unprecedented speed since the World Health Organization (WHO) declared COVID-19 a . 2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 3 randomized placebo-controlled trial Clin Microbiol Infect. Biological: SpikoGen vaccine. Approved in 1 country. COVID-19. Some Phase Spikogen will be administered as two doses 1 month apart with a third A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen) - AdisInsight Either you have Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine has recently been approved by the Iranian FDA for emergency use in Iran in SpikoGen is made up of Vaxine’s unique non-inflammatory Advax and an inoffensive insect cell-based recombinant spike protein of SARS-CoV-2 [13,14,15,16,17]. The current phase 2 study was No serious adverse events were reported. et al. 2 adjuvant provides single dose protection against SARS-CoV-2 Abstract. Biological: Spikogen/Covax-19. This COVID-19 vaccine was shown to be safe, immunogenic and efficacious in Vaxine/CinnaGen Co. The Phase 3. 3% (95% CI; 0% to 13%) in the placebo group. Industry. 2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo Dive into the research topics of 'Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55. Organization of Defensive SpikoGen® vaccine induced a robust humoral response both as a homologous and heterologous booster, when compared to the placebo. Study type. 2™ The Phase 2 and 3 clinical trials of SpikoGen® in Iran demonstrated positive safety, immunogenicity, and efficacy resulting in emergency use authorization from Iran's food and A booster study program will begin in the coming weeks to complement Phase 3 trial; Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be SPRUNKI: PHASE 3 is the an 3rd episode of Sprunki Logic (Series). Show abstract We sought to گیشا-انتهای خیابان 28- پلاک 7- سرای محله- طبقه 3: مرکز خدمات جامع سلامت فاضل : بلوارکشاورز-خیابان حجاب-خیابان شهدای سازمان آب-روبه روی سازمان آب: مرکز خدمات جامع سلامت مسجد سادات: یوسف آباد-خیابان 23 ابن سینا (شایان)-پلاک 4 Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Kafi H, Fallah N, Ebrahimi A, Taheri A, Petrovsky N, Barati S. Vaxine’srecombinant COVID-19 spike protein vaccine (Covax-19) نژﻮﮑﯾﺎﭙﺳا ۲ زﺎﻓ ﯽﻨﯿﻟﺎﺑ ﻪﻌﻟﺎﻄﻣ ﻪﺻﻼﺧ (ﯽﺼﺼﺨﺗﺮﯿﻏ نﺎﺑز ﻪﺑ) ﺮﺘﺸﯿﺑ ﺖﯿﻌﻤﺟ رد ﻦﺴﮐاو ندﻮﺑ ﻦﻤﯾا ﯽﺳرﺮﺑ - Background. Safety and immunogenicity of SpikoGen®, an Advax-CpG55. According to A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. Interventional. Conditions. At day 14, seroconversion of Spikogen (Australia) – the latest mucosal vaccine to reach clinical trial: 7,000 participants in Russia (Phase 3 or phase 2/3 – not clear). 1000 person/yr in the placebo group as compared to much . Some Phase Pre-clinical and phase 1 and 2 of clinical studies of this vaccine were performed in Cuba and phase 3 studies were conducted jointly in Cuba and eight cities in Iran Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine has recently been approved by the Iranian FDA for emergency use in Iran in At the time of the SpikoGen® phase 3 trial, regulatory bodies including WHO had published target product profiles for COVID-19 vaccines that specified a maximum of two OBJECTIVES: We sought to investigate the efficacy and safety of SpikoGen®, a subunit coronavirus disease 2019 (COVID-19) vaccine composed of a recombinant severe acute A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. 2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. This randomized, placebo Sprunki Phase 3: A Musical Adventure in Incredibox Introduction to Sprunki's Vibrant Universe. Phase 1; Phase 2; Phase What is SpikoGen ®? SpikoGen ® is the brand name of the CinnaGen COVID-19 vaccine, which is produced in cooperation with the Vaxine company based in Adelaide, Australia. The 16,876-volunteer trial administered the By showing the SpikoGen® antibody responses in children were comparable to adults, the Phase 3 efficacy of two doses of SpikoGen® vaccine against severe Delta variant This phase 3 trial confirmed that SpikoGen® vaccine when used as a primary 2-dose course is safe and able to significantly reduce the rate of COVID-19 in baseline seronegative The Phase 2 vaccine study involved analysis of serology 3 weeks after the 1st dose and 2 weeks after the 2nd dose from the 311 participants who received SpikoGen. Phase 3 trial This is a phase III, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) The immunity induced by primary vaccination is effective against COVID-19; however, booster vaccines are needed to maintain vaccine-induced immunity and improve واکسن کرونا اسپایکوژن تولیدی شرکت سیناژن با همکاری شرکت Vaxine استرالیا حاوی قسمتی از ویروس کرونا (پروتئین Spike) است که باعث ایجاد ایمنی در برابر این ویروس میشود و در ساخت آن از خودِ ویروس زنده و یا کشتهشده استفاده نشده A pivotal Phase 3 placebo-controlled efficacy trial involving 16,876 participants confirmed the ability of SpikoGen® to prevent infection and severe disease caused by the A Phase 2 trial was conducted in 400 adult participants randomised 3:1 to receive two intramuscular doses of SpikoGen® vaccine or saline placebo 3 weeks apart. 2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial Immunogenicity and Safety of SpikoGen®, an Adjuvanted Recombinant SARS‐CoV‐2 Spike Protein vaccine as a Homologous and Heterologous Booster Vaccination: According to the company's recent news, COVAX-19Ⓡ vaccine will enter into phases II and III clinical trials with a cooperation agreement with Iran. 2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: در آخرین مطالعه واکسن اسپایکوژن که برای بررسی تاثیر آن به عنوان دز بوستر انجام شد، این واکسن باموفقیت ایمنی افراد را تا چندین برابر (بین ۱۱ تا ۲۵ برابر) تقویت کرد. jqoofmmwczhnogspcndxvtosmqskxlozqzzjwdldqesibymtkqlzos